Sickle cell disease is caused by a mutation in the ␤ globin gene leading to hemoglobin S (Hb S) production. Several approaches have been explored to prevent Hb S polymerization in red blood cells and the symptoms associated with this disorder. To this end we tested a mammalian expression vector carrying a human ␤ globin antisense cDNA (pZeo␤AS) fragment in a mouse erythroleukemia cell line expressing the human ␥ and ␤ globin genes. We observed a relative reduction in ␤ globin mRNA levels compared with ␥ mRNA levels in the presence of pZeo␤AS. Moreover, analysis at the protein level showed an average 76% decrease in ␤ chains and a 517% increase in ␥ chain
Introduction
During fetal development in utero, two major switches in the types of ␤-like globin chains synthesized occur to produce normal hemoglobins. 1 The process of hemoglobin switching refers to the sequential expression of the ⑀, G␥, A␥, ␦, and ␤ globin genes, located on chromosome 11, that occurs during fetal development. Experimental data support an autonomous mechanism for ⑀ gene silencing, 2, 3 whereas for the ␥ and ␤ globin genes a competitive model has been proposed. [4] [5] [6] [7] This model is based on the ability of the locus control region (LCR) to interact with the individual ␥ or ␤ globin promoters at different time-points during development. The LCR is a powerful enhancer located approximately 20 kb upstream of the ⑀ globin gene, containing five DNase I hypersensitive sites, four of which are erythroid specific. Various erythroidspecific and ubiquitous transcription factors are known to bind to the LCR and mediate globin gene activation.
Sickle cell disease (SCD) results from a point mutation in the ␤ globin gene leading to the production of abnormal hemoglobin S (Hb S). Several approaches have been explored to prevent polymerization of Hb S in mature red blood cells (RBCs), the most promising being increased fetal hemoglobin (Hb F) production via ␥ gene activation. This can be achieved by either inhibiting the ␥ to ␤ globin switch using drugs such as butyrate 8 or the reversal of hemoglobin switching using 5-azacytidine, biosynthesis. The inhibitory effect of the antisense vector on globin expression was maintained long term in culture. The expression vector pZeo␤AS was also transfected into primary erythroid progenitors to test its effects on globin genes undergoing normal developmental switching during differentiation. We observed a relative reduction of ␤ globin mRNA levels compared with ␥ mRNA levels. These results support a novel role for antisense cDNA expression vectors as an alternative gene therapy strategy to inhibit ␤ s gene expression in sickle cell disease. Gene Therapy (2000) 7, 438-444. erythropoietin, 10 butyrate 11 or hydroxyurea. 12 More recently, hydroxyurea was shown to be an effective inducer of Hb F production and improved symptoms in sickle cell patients. 13 The quantity of hemoglobin produced in RBCs is relatively constant at 32 to 34 g/dl, which prevents precipitation of globin chains, as is known to occur in patients with thalassemia. 14 The direct mechanism for controling the absolute amount of hemoglobin in RBCs is not known. ␤-Thalassemia is a group of heterogeneous genetic disorders characterized by either deficient (␤ + ) or absent (␤ 0 ) synthesis of ␤ globin chains. The genetic defects in thalassemia include both abnormalities in transcription, 15 RNA processing, 16 translation, 17 and RNA function. 18 There are clinical data to support reactivation of ␥ gene expression under conditions where ␤ globin chains are decreased secondary to abnormalities at both the transcriptional and translational levels. Fetal hemoglobin levels as high as 32% have been reported in a subgroup of ␤-thalassemia patients. 19 While some patients have been reported to have polymorphisms in the ␥ promoter that may account for the elevated Hb F levels, other patients have normal ␥ globin promoters. The molecular mechanism for this observation is not known.
Both experimental and clinical data support a compensatory up-regulation of ␥ gene expression when the ␤ gene is inhibited. Previously, this laboratory established an in vitro system to analyze human ␥ and ␤ globin gene expression. These methods, which involved the use of antisense ␤ globin RNA transcripts, were modeled after the subgroup of thalassemia patients where translation blockade results in elevated fetal hemoglobin levels. As demonstrated previously, 20 
Results
The antisense cDNA expression vector decreased globin mRNA levels in stable MEL cell lines Three stable MEL cell lines termed ES10, ES21 and ES22 were established using the miniconstruct HS2␥␤. We observed constitutive expression for the ␥ and ␤ globin genes in all lines (Figure 1 , lanes 1 and 5) as demonstrated by RNase protection assays (RPAs). Initial experiments to inhibit ␤ globin expression were performed with two antisense oligodeoxynucleotides (ODNs), one directed toward the cap site of the ␤ globin gene and a second towards the tail, at various concentrations. There was no demonstrable effect on ␤ gene expression (data not shown). We then tested the expression vector pZeo␤AS, containing an antisense ␤ globin cDNA frag- Gene Therapy ment under the control of an SV40 promoter for the ability to inhibit ␤ globin expression. This vector was transfected into ES21 cells to establish three antisense stable lines. Given the lack of effectiveness of the ODNs, we chose to analyze the full-length ␤ globin cDNA fragment to obtain maximal inhibitory effects although there is 74% sequence homology between the ␥ and ␤ genes. We observed a decrease in mRNA levels for both ␤ and ␥ globin at day 14 ( Figure 1 , lanes 2-4) and day 28 ( Figure 1 , lanes 6-8) for all three antisense lines. Several other control MEL cell stable lines were analyzed including BS211, BS212 and BS213, established with a sense oriented ␤ globin cDNA fragment in ES21 cells, and the negative control line pZeo, established with the original pZeoSV expression vector. There was no significant change in the level of ␤ or ␥ globin mRNA for the four control cell lines ( Figure 1 , lanes 9-13). The level of RNA transcription produced by the pZeo␤AS vector was measured using a sense ␤ globin probe by RPA at different time-points. Antisense ␤ globin transcripts were detected up to day 42 (data not shown) indicating that the SV40 promoter continued to produce antisense RNA transcripts long term to account for suppressed globin gene expression.
The mRNA levels for both ␤ and ␥ globin in the three antisense lines were calculated as a ratio against mouse actin corrected for gene copy number. For the antisense stable lines ASB211, ASB212 and ASB213, the average copy number was 0.18, 0.15 and 0.15, respectively, and 0.20 for the control ES21 line. The levels of ␤ and ␥ globin mRNA were reduced an average 73.9% and 61.6% (P Ͻ 0.05), respectively (Table 1 and Figure 2 ) in all three antisense lines by day 14. The relative level of ␤ versus ␥ globin mRNA (␤/␥ ratio) decreased 31.8% indicating that the reduction in ␤ globin mRNA synthesis was greater than that for ␥ globin mRNA (Table 2) . By day 21, the ␤/␥ ratio was 68.1%, indicating that from day 14 to 21 there was a more rapid reduction in ␤ globin mRNA pro- duction than ␥ globin mRNA. Similarly, at days 28 and 35 both ␤ and ␥ globin mRNA levels remained low, but consistently ␤ globin expression was inhibited to a greater degree than that of ␥ globin (Tables 1 and 2 ). The reduction in ␤ and ␥ globin mRNA production by antisense RNA transcripts reached approximately equal levels of 77% inhibition by day 42 in culture (Tables 1 and  2 ; Figure 2 ). From these data we concluded that the antisense vector blocks both ␥ and ␤ globin gene expression, but there was a more rapid effect on the ␤ globin gene.
Decreased ␤ globin chain biosynthesis in antisense ␤ globin MEL cell lines Total protein was isolated on day 14 from untransfected MEL cells and the ES21, ASB211 and ASB213 stable lines. The level of ␤ and ␥ globin chain biosynthesis was analyzed by high-performance liquid chromatography (HPLC) which showed peaks for ␤ and ␥ globin chains in the ES21 line compared with control MEL cells not transfected with the HS2␥␤ plasmid (Figure 3a, b) . Transfections with the pZeo␤AS vector resulted in a decrease in the ␤ globin peak and an increase in the ␥ globin peak (Figure 3c ). We observed an 80% and 73% decrease in human ␤ globin chain synthesis in the ASB211 and ASB213 lines, respectively ( Figure 4) ; however, ␥ globin chain biosynthesis increased an average 233% and 802%, respectively, in the two antisense lines. Despite decreased ␥ mRNA levels at day 14, ␥ chain biosynthesis was markedly increased. A possible mechanism for this observation is a change in the rate of ␥ globin mRNA translation in response to the rapid decrease in ␤ globin mRNA levels by day 14 in the antisense lines.
Decreased globin mRNA levels in primary erythroid cultures The antisense ␤ globin expression vector, pZeo␤AS, was transfected into peripheral blood mononuclear cells isolated from normal and sickle cell patients. RPA was performed to quantitate the mRNA levels for the ␥ and ␤ globin genes as a ratio to glyceraldehyde-3-phosphate dehydrogenase (GAPD) after 21 days in culture. We observed an increase in ␤ and ␥ globin baseline mRNAs for samples obtained from sickle cell patients compared with normal subjects (Figure 5a, lanes 1 and 3) . This may be due to the increase in bone marrow activity and greater number of early progenitor cells in sickle cell samples observed by other investigators. 21 Similarly to that observed in the antisense MEL cell stable lines, globin mRNA levels decreased in erythroid progenitors transfected with pZeo␤AS ( Figure 5a , lanes 2 and 4). Compared with control cultures (erythroid progenitors transfected with the original pZeoSV plasmid), ␤ and ␥ globin mRNA production decreased an average 83% and 67% (P Ͻ 0.05), respectively, for both normal and sickle erythroid progenitors (Figure 5b, c) . In addition, the ␤/␥ mRNA ratio decreased 63% for normal and 77% for sickle progenitors indicating that the reduction in ␤ globin mRNA synthesis was significantly greater than that of ␥ globin, a result similar to that observed for the stable MEL cell lines. Moreover, normal ␤ globin antisense RNA transcripts produced by pZeo␤AS inhibited the mutant ␤ s globin gene in samples obtained from sickle cell patients.
Discussion
Antisense RNA is a potentially powerful tool for creating dominant negative mutations by blocking target genes. 22 The antisense approach has been used to address fundamental questions in molecular and cellular biology in animal and human diseases. Among the perturbation strategies that are RNA directed, the most widely used for modulating globin gene expression are catalytic RNA molecules (or ribozymes), 23 antisense RNA 24 and antisense ODNs. 25 Ribozymes have been shown to inhibit ␥ gene expression in K562 erythroleukemia cells and human erythroid progenitors 23 but this approach has proved to be a technical challenge and not easily adaptable for general use. When using antisense ODNs to down-regulate gene expression, it is necessary to repeatedly add synthetic antisense ODNs, which is time-consuming and expensive, thereby limiting their usefulness in clinical practice. To circumvent this problem, a continuous source of antisense RNA transcripts can be obtained using an expression vector to produce stable transformants. 24 In this study, we have shown that the use of a full-length ␤ globin antisense cDNA allows longterm regulation of globin gene expression in both erythroleukemia cell lines and primary cultured human blood cell progenitors following stable transfection. The use of this transfection system for ex vivo modification of human progenitor cells may prove beneficial for gene therapy strategies in sickle cell disease.
Several clinical approaches have been explored to pre- vent polymerization of Hb S, the most promising being increased Hb F production using drug therapy. Inhibition of the ␥ to ␤ globin switch can be achieved using butyrate compounds 8 or reversed by hydroxyurea, 13 but these drugs require repetitive dosing or have significant sideeffects. Our system using antisense RNA transcripts to increase fetal hemoglobin has the potential to eliminate the need for frequent dosing, providing an alternative gene therapy approach. Moreover, in naturally occurring thalassemia variants premature termination of translation can occur due to frame shift mutations leading to a thalassemia intermedia phenotype with decreased ␤ globin chains and increased fetal hemoglobin production. 23 Therefore, in this study we may have established a model system to recapitulate these naturally occurring Gene Therapy mutations which may provide a powerful mechanism for investigating thalassemia. We observed inhibition for both the ␤ and ␥ genes following expression of antisense ␤ globin message, presumably due to the high degree of homology (74%) between their cDNA sequences. However, by day 14 ␤ globin chain biosynthesis was greatly reduced while ␥ globin chains were increased in a compensatory manner. This suggests a possible relationship between the reduction in the ␤/␥ globin mRNA ratio and increased ␥ globin chain biosynthesis. The reasons for this effect are not clear, although several possibilities can be envisioned. For example, changes may occur in the rate of ␥ mRNA translation either through increased rates of chain initiation or elongation, to account for the significant increase in ␥ globin chain biosynthesis. Alternately, differences in the relative stability for the ␤ versus ␥ globin sense-antisense RNA duplexes may account for the increased ␥ chain synthesis we observed. These speculations will need to be tested experimentally.
The HS2␥␤ plasmid used to establish the ES21 cell line contains ␥ and ␤ globin genes in close proximity to HS2. As a result, the proper spacing between the LCR element and the globin genes is not maintained in the miniconstruct. The net result is a significant level of ␥ globin mRNA in our control lines and a lack of hemoglobin switching. Furthermore, the chromosome 11 related regulatory mechanism for sequential expression of the ␥ and ␤ genes is not maintained in this model of hemoglobin switching. To overcome these limitations, the pZeo␤AS vector was analyzed in an alternative model for normal ␥ to ␤ globin switching using primary erythroid progenitors derived from peripheral blood mononuclear cells. We observed decreased levels for both ␤ and ␥ globin mRNA, but the ␤/␥ mRNA ratio decreased significantly indicating that the reduction of ␤ globin mRNA levels was greater than that of ␥ globin. We speculate that one might expect to observe a similar increase in ␥ globin chain synthesis, although mRNA levels were decreased. Future studies will test this possibility. In addition, it will also be interesting to test the long-term effects of the antisense ␤ globin cDNA expression vector in normal and sickle erythroid progenitors at both the mRNA and pro- tein levels during development and in the setting of embryonic stem cell cultures.
As the design of ODNs and antisense vectors improves, a vast array of clinical disorders can potentially be treated by this approach. Our data support a future role for antisense expression vectors as a new gene therapy strategy for sickle cell disease. 
Materials and methods
Cell culture MEL cells were maintained in suspension cultures at 37°C, 5% CO 2 in Iscove's modified Dulbecco's medium (IMDM) containing 10% fetal bovine serum (FBS), penicillin (100 U/ml), and streptomycin (0.1 mg/ml). For experiments performed in primary cultures, mononuclear cells were isolated from the peripheral blood of normal and sickle cell individuals by density gradient centrifugation using Histopaque-1077 (Sigma Biochemical, St Louis, MO, USA). The mononuclear cells were maintained in suspension cultures as described by Fibach et al 26 in phase 1 media: IMDM with 10% FBS and 10% conditioned medium (StemCell Technologies, Vancouver, BC, Canada). After 5 days the cells were resuspended in phase 2 media: IMDM containing 30% FBS, 1% bovine serum albumin, 1 × 10 −5 m ␤ 2-mercaptoethanol, 1.5 mm l-glutamine, 1 × 10 −6 m dexamethasone, and 1 U/ml erythropoietin for 17 days. Informed consent was obtained for all blood samples drawn following guidelines from the University of South Alabama Institutional Review Board.
Plasmid constructs
The HS2␥␤ plasmid was a gift from Dr David Donze. 27 This plasmid contains a 1.9 kb HS2 fragment, a 3.3 kb ␥ gene, and a 4.1 kb ␤ gene. HS2␥␤ was used to establish three stable MEL cell lines: ES10, ES21 and ES22. The entire ␤ gene cDNA (439 bp) was produced by reverse transcription (RT)-PCR. The following primers were used: forward primer (5′-GG GGT ACC ATG GTG CAC ATG ACT-3′) which contains a KpnI site added to the 5′ end and a reverse primer (5′-GAAA AGT ACT TTA GTG ATA CTT GTG GGC-3′) with a ScaI site added to the 3′ end. The PCR fragment was cloned into the eukaryotic vector pZeoSV (Invitrogen, Carlsbad, CA, USA) at the ScaI and KpnI restriction sites to produce the expression ) grown at log phase were washed with phosphate-buffered saline and resuspended in IMDM without FBS, along with 10 g of linearized HS2␥␤ plasmid and 1 g of Neo plasmid (Stratagene, La Jolla, CA, USA). Cells and plasmids were placed in a 0.4 cm gap cuvette and cells were electroporated at 200 V and 960 F in a Bio-Rad Gene Pulser (Hercules, CA, USA) apparatus. On day 3, G418 at a concentration of 0.7 mg/ml was added to select for resistant clones. Three stable lines, ES10, ES21 and ES22 were established. After 2 weeks in culture, the cells were harvested and total RNA isolated using RNA STAT-60 (Tel-Test 'B', Friendswood, TX, USA) according to the manufacturer's instructions. RPAs were performed to quantitate mouse actin (mActin) and ␥ and ␤ globin mRNA production levels (see details below). For the ␤ globin antisense cDNA stable lines, ES21 cells were transfected with 10 g of the linearized pZeo␤AS plasmid by electroporation and the stable lines were established as described above after selecting for zeocin (50 g/ml)-resistant clones.
Primary erythroid cell transfections
Five micrograms of pZeo␤AS in IMDM were mixed with an equal volume of IMDM containing 25 g of lipofectant reagent (DMRIE-C, Life-Technologies, Gaithersburg, MD, USA). This mixture was used to resuspend 2 × 10 6 peripheral blood mononuclear cells isolated as described above. After incubation at 37°C with 5% CO 2 for 4 h, IMDM, FBS and conditioned medium (StemCell Technologies) were added overnight. On day 2, the cells were resuspended and maintained in phase 1 media as described for primary erythroid cells above. On day 5, zeocin at a concentration of 50 g/ml was added to phase 2 media to select for resistant erythroid progenitors.
RNase protection assay
Total RNA was isolated from MEL and primary erythroid cells using RNA STAT-60 (Tel Test 'B') according to the manufacturer's instructions. Globin mRNA was quantified by RPA with the following RNA probes labeled with ␣-32 P UTP: pT 7 A ␥ linearized with BstEII to give a 170 bp protected fragment for ␥ globin mRNA, pT 7 H␤ linearized with HindIII to give a 205 bp protected fragment for ␤ globin mRNA, and pT 7 M␣ linearized with HindIII to yield a 128 bp protected fragment. Two additional probes, pTri-actin (Ambion, Austin, TX, USA), that yielded a 305 bp mActin protected fragment, and human GAPD (Ambion), which yielded a 316 bp protected fragment, were used as internal controls. The final probe constructed was pSP 6 H␤ that contained a sense oriented ␤ globin cDNA (439 bp) fragment designed to detect antisense RNA transcripts produced by pZeo␤AS. RNA (2 g) was hybridized overnight at 45°C with 10 6 c.p.m. of each radiolabeled RNA probe produced by in vitro transcription (Maxiscript Kit; Ambion). After digestion with RNase A, the RNA species were separated on a 6% polyacrylamide-8M urea gel and phosphorimager analysis (GS-250 Molecular Imager, BioRad) was performed to quantify the human GAPD, h␤, h␥, m␣ and mActin mRNA levels.
Gene copy number Genomic DNA was isolated from the various stable cell lines. Three concentrations of DNA (10, 1 and 0.1 g) were immobilized on to a nitrocellulose membrane and hybridized with a human ␤ globin gene probe (205 bp) produced by PCR amplification. Phosphorimager analysis was used to determine the relative intensities of the signals obtained for the DNA from the stable lines compared to the human genomic DNA standard (Promega, Madison, WI, USA) which contains two copies of the ␤ globin gene. The copy number was calculated as the signal intensity of the sample divided by half of the signal intensity of human genomic DNA. Multiple analyses were performed for each stable line.
High performance liquid chromatography Globin chain biosynthesis was quantified by HPLC analysis as previously published. 28 In brief, cells were harvested, total cellular lysates prepared and protein concentrations determined using the Bradford assay. Cellular protein (100 g) was lyophilized and resuspended in 500 l of 0.1% trifluoroacetic acid, then loaded on to a C 4 column (Vydac Separations Group, Hesperia, CA, USA) and eluted with a Beckman System Gold HPLC apparatus. The gradient was composed of 36% acetonitrile in 0.1% trifluoroacetic acid for buffer A, and 46% acetonitrile in 0.1% trifluoroacetic acid for buffer B. Initial conditions were 23% A and 77% B. Ultraviolet absorbency of the column eluant was monitored at 220 nm. For the three stable lines analyzed, ES21, ASB211 and ASB213, the protein quantification was performed for two independent experiments for each of the constructs.
Statistics
For ␤ and ␥ mRNA levels at the various time-points, all values are presented as the mean ± standard error of the mean for three to four independent experiments. The data were evaluated using the unpaired Student's t test: P values less than 0.05 were considered to be statistically significant.
